Navigation Links
Pharmasset Receives $10 Million of Working Capital
Date:3/28/2008

PRINCETON, N.J., March 28 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) received a second loan of $10 million from Horizon Technology Finance under an existing working capital loan agreement that was entered into during September 2007. Pharmasset received the first loan of $10 million in October 2007 and, at its option, may receive a third loan of $10 million by November 30, 2008, provided certain conditions are satisfied.

"We believe that our existing cash resources, together with a third loan available under our working capital agreement and anticipated payments under our existing HCV collaboration agreement with Roche, will be sufficient to fund our projected cash requirements for the next 18 months," stated Kurt Leutzinger, Pharmasset's Chief Financial Officer. "In light of the recent stock market volatility, this facility has proved to be valuable in providing flexibility regarding the timing of any future equity financings."

For each $10 million loan funded, Pharmasset will pay interest only for the first 15 months followed by 30 equal monthly installments of principal and accrued interest. The interest rate for the initial loan and the second loan will be 12%. In addition, upon entering into the working capital loan agreement, Pharmasset issued to Horizon a seven-year warrant to purchase up to 149,377 shares of common stock at an exercise price of $12.05 per share. The warrant is currently exercisable for up to 66,390 shares associated with the first loan and up to 49,793 shares associated with the second loan. The remaining 33,194 shares will become exercisable upon the funding of the third loan if it occurs.

About Horizon

Founded in 2003, Horizon Technology Finance, LLC is an independent ve
'/>"/>

SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Pharmasset Appoints Herbert J. Conrad as a Director
2. Pharmasset to Present at Cowen & Companys Health Care Conference on Tuesday, March 18th
3. Pharmasset to Present at Susquehannas Second Annual SIGnificant Investment Options in Healthcare Conference on Wednesday, March 5th
4. Pharmasset to Present at the BIO CEO & Investor Conference 2008 on Monday, February 11th
5. Pharmasset Reports Fiscal Year End 2007 Financial Results
6. Pharmasset Appoints Michael Rogers as Chief Development Officer
7. Pharmasset to Present at Three Investor Conferences in November 2007
8. Pharmasset Accesses up to $30 Million of Working Capital
9. Pharmasset to Present at the UBS Global Life Sciences Conference on Monday, September 24th
10. Pharmasset and Roche to Present R7128 Data at the 14th International Symposium on Hepatitis C Virus and Related Viruses
11. Memory Pharmaceuticals Receives Audit Opinion Containing Going Concern Qualification
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... PA (PRWEB) December 19, 2014 ... leading developer and manufacturer of needle-free injection technology, ... agreement with Immunomic Therapeutics, Inc. (“ITI”) for ITI ... device with its LAMP™ vaccine platform. , ... an exclusive Worldwide license to the Biojector®-2000 that ...
(Date:12/19/2014)... Charm Sciences is pleased to announce ... of Aflatoxin M1 in raw commingled milk is the ... validation. The peer reviewed report of the validation by ... Agricultural and Fisheries Research (ILVO-T&V) has been published by ... the most toxic aflatoxin and a known carcinogen, can ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of ... Nick Maroulis, Pharm.D. to the newly created position of ... this position, Dr. Maroulis will continue to manage the ... our multi-site pharmacies as the company expands. Dr. Maroulis ... time he has served in many different capacities in ...
(Date:12/19/2014)... EVANSTON, Ill. , Dec. 19, 2014 ... to develop novel drugs for diseases of the central ... Ph.D., president and chief executive officer, will present at ... Dr. Riedel,s presentation will take place at 3:00 p.m. ... St. Francis in San Francisco, Calif. ...
Breaking Biology Technology:Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3Charm Sciences Achieves Independent Validation of First 15 Minute Quantitative Screening Method for Aflatoxin M1 2BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Naurex to Present at 33rd Annual J.P. Morgan Healthcare Conference 2
... COLLEGE PARK, Md., Dec. 23, 2010 Martek Biosciences, ... Institute (Mtech) at the University of Maryland, entered an ... Dutch company Royal DSM NV for $1.1 billion, the ... Martek is the second company sold ...
... Pathfinder LLC, a private biotechnology company focused on ... ("Pathfinder"), and SyntheMed, Inc. (OTC Bulletin Board: ... today announced that they have entered into a definitive ... Cell Therapy, Inc." and the combined company will operate ...
... University of Santiago de Compostela (USC) have analysed levels of ... Galicia. The results show that 34% of these schools exceed ... Excessive inhalation of radon is associated with lung cancer. ... 34% had radon levels in excess of 400 Bequerels/m3 in ...
Cached Biology Technology:Martek Is Second Mtech Company Sold for More Than $1 Billion in Three Years 2Martek Is Second Mtech Company Sold for More Than $1 Billion in Three Years 3Martek Is Second Mtech Company Sold for More Than $1 Billion in Three Years 4Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement 2Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement 3Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement 4Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement 5Pathfinder LLC and SyntheMed, Inc. Announce Merger Agreement 634 percent of Galician secondary schools exceed maximum recommended radon levels 2
(Date:12/17/2014)... , Dec. 15, 2014 Research and Markets ... addition of the "Samsung Galaxy S5 - ... report to their offering. ... totally different sensing technology than the iPhone 5S, ... sensor in its product. The Galaxy ...
(Date:12/17/2014)... , Dec. 16, 2014  Automation is fundamentally ... more evident than at international borders. Over the ... scanners have allowed veteran travelers to self process ... Control (APC) Kiosks at an increasing number of ... According to Maxine Most ...
(Date:12/11/2014)... 10, 2014  Data Sciences International (DSI), the ... a new series of digital telemetry implants to ... M series, part of the PhysioTel™ Digital platform, ... possible physiologic data when incorporating functional endpoints into ... to toxicology studies has evolved from short ECG ...
Breaking Biology News(10 mins):Samsung Galaxy S5 - Home Button Synaptics Fingerprint Sensor Technology Analysis 2Automated Border Control (ABC) Transforms the Global Travel Experience With More Than 2500 ABC eGates and APC Kiosks Deployed In Airports, Seaports, and Land Borders Worldwide 2New telemetry implants expected to change how large animal toxicology studies are conducted 2
... developed from plant biomass and purpose-grown crops can substantially ... report says, but only through the wise allocation of ... the state. That,s the conclusion of "California Energy ... California Council on Science and Technology (CCST) co-authored by ...
... proposed an answer to the long-running debate as to how ... core-driven magnetic field, oceans of liquid water, dynamic climate and ... known Universe. Life arose on Earth over three and a ... planetary scale calamities such as the impacts of massive meteorites, ...
... Methanosarcina acetivorans lives off everything it can metabolize ... is not yet clear. Scientists at the Ruhr-Universitt Bochum ... USA have identified a protein that might act as ... and found both similarities and differences to the system ...
Cached Biology News:Biofuels will play integral role in California's energy future, says new EBI study 2Biofuels will play integral role in California's energy future, says new EBI study 3New study proposes solution to long-running debate as to how stable the Earth system is 2How Archaea might find their food 2
... is produced by a patented microwave process ... more consistent, even cell attachment, increased cell ... and growth uunder difficult conditions, including reduced ... provide a more ecominic alternative to expensive ...
...
Mouse monoclonal antibody raised against a partial recombinant ARHGEF11. NCBI Entrez Gene ID = ARHGEF11...
... Cell Lines ,High Quality, Functionally-Validated, Ion Channel ... known for having a critical role in ... a key function in pain, CNS and ... have been investigated in therapeutic areas, such ...
Biology Products: